Concepedia

Barry Turnbull

BT

Statistics

Publications

11

Citations

1.3K

H-Index

11

Active since

2005

Affiliations

BioBridges (United States)(Current)

Dana-Farber Cancer Institute

Harvard University

University of Maryland, Baltimore

Barry Turnbull is an author at BioBridges (United States) specializing in medicine, immunology, and clinical immunology.

Publications per year

2005–2018

11

Publications

11

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Ian W. Flinn, Peter Hillmen, Marco Montillo et al. · Blood · 2018 · 341 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

Steven P. Treon, Mark Hansen, Andrew R. Branagan et al. · Journal of Clinical Oncology · 2005 · 257 citations · Full text

Life Sciences, Genetics, Immunology +15

Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia

Steven P. Treon, Christina Tripsas, Kirsten Meid et al. · Blood · 2014 · 177 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +4

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis et al. · Blood · 2008 · 147 citations · Full text

Life Sciences, Hematology, Immunology +8

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

Steven P. Treon, Christina Hanzis, Robert Manning et al. · British Journal of Haematology · 2011 · 101 citations · Full text

Medicine, Immunology, Internal Medicine +13

1–5 of 11